Mr. Arun Menawat reports

PROFOUND MEDICAL ANNOUNCES STRATEGIC DISTRIBUTION AGREEMENT WITH GETZ HEALTHCARE TO BRING TULSA-PRO® TO AUSTRALIA AND NEW ZEALAND

Profound Medical Corp. has entered into an exclusive distribution and supply agreement for its Tulsa-Pro system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables, in Australia and New Zealand.

The Tulsa procedure, performed using Profound's Tulsa-Pro system, is a significant advancement in prostate care. Instead of surgery or radiation, treatment is performed inside an MRI suite using robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures. Tulsa-Pro is the only AI-powered, MR-guided robotic system for prostate therapy, enabling real-time MRI thermography and autonomous temperature control. This allows physicians to see, monitor and adjust treatment throughout the procedure -- delivering personalized therapy with exceptional precision.

"Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand," commented Getz Healthcare ANZ managing director, Derek Foltin. "The Tulsa-Pro system strengthens our commitment to deliver innovative, clinically proven technologies that improve patient outcomes and further advances our position in prostate cancer surgery and minimally invasive therapies."

"Like in many other regions around the globe, prostate cancer is the most commonly diagnosed cancer in men in Australasia," said Arun Menawat, Profound's chief executive officer and chairman. "We are excited to gain access to this significant market for Tulsa-Pro. Beyond Australia and New Zealand, we are actively pursuing other potential opportunities to expand our strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific."

As user interest in Profound's technologies continues to build, the company is deploying its own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate- or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The Tulsa procedure employs real-time MR guidance for precision to preserve patients' urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55 to 57 degrees Celsius. The Tulsa procedure is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with the Tulsa procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most Tulsa patients report quick recovery to their normal routine. Tulsa-Pro is CE marked, Health Canada approved and 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumours and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

We seek Safe Harbor.